Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32421451)

  • 21. Signaling cross-talk in the resistance to HER family receptor targeted therapy.
    Yamaguchi H; Chang SS; Hsu JL; Hung MC
    Oncogene; 2014 Feb; 33(9):1073-81. PubMed ID: 23542173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [MET receptor inhibition: Hope against resistance to targeted therapies?].
    Hochart A; Leblond P; Le Bourhis X; Meignan S; Tulasne D
    Bull Cancer; 2017 Feb; 104(2):157-166. PubMed ID: 27863726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of targeted therapy for gastrointestinal tumors.
    Rolfo C; Bronte G; Sortino G; Papadimitriou K; Passiglia F; Fiorentino E; Marogy G; Russo A; Peeters M
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):875-85. PubMed ID: 24957206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
    Martins M; Mansinho A; Cruz-Duarte R; Martins SL; Costa L
    Adv Exp Med Biol; 2018; 1110():113-131. PubMed ID: 30623369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy.
    Moehler M; Schwarz S; Wagner AD
    Curr Cancer Drug Targets; 2011 Jul; 11(6):681-7. PubMed ID: 21651462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.
    Bregni G; Sciallero S; Sobrero A
    JAMA Oncol; 2019 May; 5(5):605-606. PubMed ID: 30869746
    [No Abstract]   [Full Text] [Related]  

  • 30. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
    Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
    Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
    Takegawa N; Yonesaka K
    Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure].
    Cheung DY; Kim JK
    Korean J Gastroenterol; 2013 Mar; 61(3):117-27. PubMed ID: 23575230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
    Huynh JC; Schwab E; Ji J; Kim E; Joseph A; Hendifar A; Cho M; Gong J
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32384640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical update on K-Ras targeted therapy in gastrointestinal cancers.
    Pant S; Hubbard J; Martinelli E; Bekaii-Saab T
    Crit Rev Oncol Hematol; 2018 Oct; 130():78-91. PubMed ID: 30196915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The drug treatment research of gastrointestinal cancer in China.
    Ren C; Xu RH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e3-e6. PubMed ID: 32591201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.